According to bluebird bio 's latest financial reports the company's current revenue (TTM) is $21.72 M. In 2022 the company made a revenue of $3.59 M an increase over the years 2021 revenue that were of -$37.23 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $21.72 M | 503.84% |
2022 | $3.59 M | -109.67% |
2021 | -$37.23 M | -114.85% |
2020 | $0.25 B | 461.25% |
2019 | $44.67 M | -18.15% |
2018 | $54.57 M | 54.06% |
2017 | $35.42 M | 475.58% |
2016 | $6.15 M | -56.29% |
2015 | $14.08 M | -44.61% |
2014 | $25.42 M | 25.97% |
2013 | $20.18 M | 5835.59% |
2012 | $0.34 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Sanofi SNY | $50.35 B | 231,695.60% | ๐ซ๐ท France |
Merck MRK | $60.11 B | 276,591.52% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $0.17 B | 711.16% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | $0.11 B | 419.03% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | $0.01 M | -99.95% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 11,035.17% | ๐บ๐ธ USA |